Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents [Hematologic Malignancy]
Conclusion
Lenalidomide yields sustained RBC-TI in 26.9% of RBC transfusion–dependent patients with lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents. Response to lenalidomide was associated with improved HRQoL. Treatment-emergent adverse event data were consistent with the known safety profile of lenalidomide. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Santini, Almeida, Giagounidis, Gropper, Jonasova, Vey, Mufti, Buckstein, Mittelman, Platzbecker, Shpilberg, Ram, del Canizo, Gattermann, Ozawa, Risueno, MacBeth, Zhong, Seguy, Hoenekopp, Beach, Fenaux Tags: Chemotherapy Hematologic Malignancy Source Type: research
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion
First-line nivolumab monotherapy demonstrated a tolerable safety profile and durable responses in first-line advanced NSCLC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gettinger, Rizvi, Chow, Borghaei, Brahmer, Ready, Gerber, Shepherd, Antonia, Goldman, Juergens, Laurie, Nathan, Shen, Harbison, Hellmann Tags: Chemotherapy Thoracic Oncology Source Type: research
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]
Conclusion
The safety profile of nivolumab plus PT-DC was consistent with that expected for individual agents; however, treatment discontinuation related to AEs was greater with the combination. Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Rizvi, Hellmann, Brahmer, Juergens, Borghaei, Gettinger, Chow, Gerber, Laurie, Goldman, Shepherd, Chen, Shen, Nathan, Harbison, Antonia Tags: Chemotherapy Thoracic Oncology Source Type: research
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer [Rapid Communication]
Conclusion
ESR1 mutation analysis in plasma after progression after prior AI therapy may help direct choice of further endocrine-based therapy. Additional confirmatory studies are required. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Fribbens, OLeary, Kilburn, Hrebien, Garcia-Murillas, Beaney, Cristofanilli, Andre, Loi, Loibl, Jiang, Bartlett, Koehler, Dowsett, Bliss, Johnston, Turner Tags: Combined Modality, Hormonal Therapy, Translational Oncology, Rapid Communications Source Type: research
Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Alumkal, Beer Tags: Clinical Trials, Systemic Therapy EDITORIALS Source Type: research
Long Days Journey Into Night for Lower-Risk Myelodysplastic Syndromes [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Sekeres Tags: Chemotherapy EDITORIALS Source Type: research
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Gainor Tags: Translational Oncology, Chemotherapy EDITORIALS Source Type: research
Evolving Role of the Estrogen Receptor as a Predictive Biomarker: ESR1 Mutational Status and Endocrine Resistance in Breast Cancer [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Lauring, Wolff Tags: Hormonal Therapy, Translational Oncology, Cancer Biomarkers EDITORIALS Source Type: research
2016 ASCO Presidential Address: "Collective Wisdom: The Future of Patient-Centered Care and Research" [PRESIDENTIAL ADDRESS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Vose Tags: Notes from the Editors PRESIDENTIAL ADDRESS Source Type: research
Advertising [ONCOLOGY CAREER CENTER]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Tags: ONCOLOGY CAREER CENTER Source Type: research
ERRATA [Errata]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Tags: Errata Source Type: research
Reply to D. Vordermark and T. Pelz and R. Mazzola et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: van Nimwegen, Cutter, Schaapveld, Darby, Aleman, van Leeuwen Tags: CORRESPONDENCE Source Type: research
Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Mazzola, Giaj Levra, Alongi Tags: CORRESPONDENCE Source Type: research
Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - August 14, 2016 Category: Cancer & Oncology Authors: Vordermark, Pelz Tags: CORRESPONDENCE Source Type: research
